Medical Xpress - Study Shows Longer Treatment for Children With Langerhans Cell Hystiocytosis Improves Survival Rates

Stephan Ladisch, M.D., professor of pediatrics and professor of biochemistry and molecular biology, was featured in Medical Xpress for recently published research in the American Society of Hematology journal, Blood. The international study found that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis (MS-LCH) can achieve survival rates as high as 84 percent—a full 15 percent improvement over his previous clinical trial. This research was also featured in Science Codex.